Comparing leronlimab to insulin dosage for safety.
Post# of 148150
The highest dosage that I know of used in IV was back when Progenics was doing trials with no safety problems. What safety problems exist in the 700mg sub-q dose? none. Why? because all that leronlimab does is bind to the CCR5 receptor. It doesn't break down in the liver causing liver enzymes to rise. It has shown no negative interaction except redness and swelling at the injection site which IV would eliminate. That is the positive of having a large molecule.
If the FDA is as clueless as it has no far shown in regard to leronlimab a 1b trial could be completed in extremely short order.
Now go back and do some due diligence on aviptadil and despair.